FDA approves Tryngolza (olezarsen) for severe hypertriglyceridemia (sHTG); first indication for acute pancreatitis reduction

Ionis Pharmaceuticals/Olezarsen (Tryngolza)

The FDA approved Tryngolza for severe hypertriglyceridemia, expanding its indication beyond familial chylomicronemia syndrome. Tryngolza became the first and only therapy to reduce acute pancreatitis events in this larger patient population, with results from CORE and CORE2 showing up to 72% triglyceride reduction and 85% reduction in pancreatitis risk.